Insanity is doing the same thing over and over again and expecting different results. – Variously Attributed [This blog was written and published on Monday July 20th, two days prior to the announcement of the results of Eli Lilly’s clinical trials of solanezumab for Alzheimer’s.] Until now, there have been only two globally-approved drugs for […]
Alzheimer’s disease steals our souls. We lose our humanity when it destroys the neurons that make up a critical part of our brains, but why those neurons die has always remained a mystery since “senility” was first noted, thousands of years ago. Even in the past century, since it was first described clinically by Dr. […]
Last weekend, a global entrepreneur asked me about the difference between much of the current research and what we’re doing. He cited the example of a particular compound (NAD+), but any number of other compounds could be given as examples. My answer was that most researchers are focused on their one particular tree and can’t […]
Many of you have asked about Helen Blau’s work at Stanford, using telomerase mRNA [FASEB Journal]. Helen sent me a copy of her article when it came out and I’m a serious fan of her work. As some of you know from my upcoming book, The Telomerase Revolution, there are four approaches to resetting telomeres: […]
My new book, The Telomerase Revolution, is now finished and is being copy edited by the publisher. Oddly enough, it’s already selling well in preorders. Amazon.com says that it is now the “#1 release in medical research”, which is a delightful surprise, since it won’t actually be published and available to the public until October. […]
Every several weeks, I notice publication of yet another article trumpeting another aspect of Alzheimer’s. Where once it was APOE-4, AB42, or SS31 (an antioxidant peptide), more recent work emphasizes arginine metabolism in the microglia. The good news is that research community has — ponderously and hesitantly — finally begun to shift the clinical focus […]
As I write this in March of 2015, there are 1,315 registered clinical studies of potential interventions for Alzheimer’s disease (see ClinicalTrials.gov). While it is hard to define clearly, many of these studies deal with nursing issues, rather than medical interventions aimed at preventing or curing the pathology itself. Of those that are testing potential […]
The notion that all aging is ultimately cell aging is a novel hypothesis and one with growing support. Recent studies in genetics and cell biology are consistent with this view. Criticism of the model is largely reflective of inadequate understanding of both the model itself and human pathology. Hutchinson-Gilford progeria is a segmental progeria that […]